IMMUNETHEP
Biotech start-up company that is developing broad coverage anti-bacterial immunotherapies . Learn more
Launch date
Employees
Cantanhede Coimbra (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
| % growth | - | 100 % | (16 %) | 6 % | (93 %) | 6766 % | 90 % |
| EBITDA | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | <1m |
| % EBITDA margin | (187 %) | (179 %) | (303 %) | (246 %) | (5924 %) | (83 %) | 32 % |
| Profit | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | <1m |
| % profit margin | (193 %) | (147 %) | (255 %) | (205 %) | (4834 %) | (69 %) | 14 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
N/A | Angel | ||
N/A | Seed | ||
$100k | Grant | ||
N/A | - | ||
N/A | Grant | ||
€2.5m | Grant | ||
N/A | Early VC | ||
| Total Funding | $2.9m | ||
Related Content
Recent News about IMMUNETHEP
EditMore about IMMUNETHEP
EditDeveloper of anti-bacterial immunotherapies designed to prevent multi-bacterial infections. The company offers therapies including the development of neonatal vaccines to protect neonates from bacterial infections inside the mother's womb, enabling patients to develop their immunity and prevent their diseases through advanced healthcare methods.
Keywords: Healthcare Devices, Services, Supplies, Antimicrobial Resistance, Bacterial Infection, Immunity Development, Immunotherapy Company, Immunotherapy Product, Vaccines For Infectious Disease.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.